Literature DB >> 30328116

Association of autoimmunity and long-term complete remission in patients with Sézary syndrome treated with mogamulizumab.

P Bonnet1, M Battistella2, M Roelens3, C Ram-Wolff1, F Herms1, L Frumholtz1, J-D Bouaziz1, P Brice4, H Moins-Teisserenc3, M Bagot1, A de Masson1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30328116     DOI： 10.1111/bjd.17320

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN： 0007-0963            Impact factor:   9.302


× No keyword cloud information.
  6 in total

1.  Mogamulizumab Forecast: Clearer Patients, with a Slight Chance of Immune Mayhem.

Authors:  Cecilia Larocca; Thomas S Kupper; Nicole R LeBoeuf
Journal:  Clin Cancer Res       Date:  2019-10-15       Impact factor: 12.531

Review 2.  Mogamulizumab-induced Mucocutaneous Lichenoid Reaction: A Case Report and Short Review.

Authors:  Megan H Trager; Donatienne de Clippelé; Caroline Ram-Wolff; Adèle de Masson; Marie-Dominique Vignon-Pennamen; Maxime Battistella; Laurence Michel; Martine Bagot; Gabor Dobos
Journal:  Acta Derm Venereol       Date:  2020-05-28       Impact factor: 3.875

Review 3.  Monoclonal Antibodies in Dermatooncology-State of the Art and Future Perspectives.

Authors:  Malgorzata Bobrowicz; Radoslaw Zagozdzon; Joanna Domagala; Roberta Vasconcelos-Berg; Emmanuella Guenova; Magdalena Winiarska
Journal:  Cancers (Basel)       Date:  2019-09-24       Impact factor: 6.639

4.  Alopecia areata after mogamulizumab treatment.

Authors:  Neel S Raval; Nora A Alexander; Karlee De Monnin; Christine C Yokoyama; Neha Mehta-Shah; Ilana S Rosman; Amy C Musiek
Journal:  JAAD Case Rep       Date:  2021-11-18

5.  Impact of Mogamulizumab in Real-Life Advanced Cutaneous T-Cell Lymphomas: A Multicentric Retrospective Cohort Study.

Authors:  Marie Jouandet; Inès Nakouri; Lawrence Nadin; Alice Kieny; Mahtab Samimi; Henri Adamski; Gaëlle Quéreux; Guillaume Chaby; Anne Dompmartin; Jean-Matthieu L'Orphelin
Journal:  Cancers (Basel)       Date:  2022-03-25       Impact factor: 6.639

6.  CCR8 is a new therapeutic target in cutaneous T-cell lymphomas.

Authors:  Jérôme Giustiniani; Gabor Dobos; Hélène Moins-Teisserenc; Tiago Eustaquio; Maxime Battistella; Nicolas Ortonne; Caroline Ram-Wolff; Jean-David Bouaziz; Anne Marie-Cardine; Samia Mourah; Martine Bagot; Thomas S Kupper; Rachael A Clark; Armand Bensussan; Adèle de Masson
Journal:  Blood Adv       Date:  2022-06-14
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.